AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Moleculin Biotech, Inc.
Video analysis: MBRX
All videosNo video analysis for this stock yet. Request one from our team.
News: MBRX
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.
Moleculin Biotech (NASDAQ:MBRX) Stock Crosses Below Fifty Day Moving Average – Time to Sell?
Moleculin Biotech, Inc. (NASDAQ: MBRX - Get Free Report) shares crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $1.21 and traded as low as $0.7735. Moleculin Biotech shares last traded at $0.8299, with a volume of 531,906 shares trading hands. Analysts Set New
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
- Video webcast now available here
Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the unblinded efficacy readout in December 2026 to February 2027 timeframe MIRACLE trial Part B initiation expected in the first half of 2027 following optimal dose selection Cash position, including $9.3 million raised after quarter-end, expected to fund operations into the first quarter of 2027 Absence of cardiotoxicity continues in the MIRACLE trial HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the second quarter ended June 30, 2026, and highlighted continued progress in its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML). Moleculin continues to advance the pivotal Phase 2/3 MIRACLE trial following positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A, which showed complete remission rates at least three times greater than the control arm.
Moleculin Announces Pricing of $9.3 Million Public Offering
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof), and warrants (the "Common Warrants") to purchase up to 37,130,001 shares of common stock at a combined public offering price of $0.
Moleculin Announces Pricing of $9.3 Million Public Offering
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof), and warrants (the “Common Warrants”) to purchase up to 37,130,001 shares of common stock at a combined public offering price of $0.75 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants. The Common Warrants will be immediately exercisable at an exercise price of $0.75 per share and will expire five years following the initial exercise date. The offering is expected to close on or about August 3, 2026, subject to satisfaction of customary closing conditions.
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Prior venetoclax failure - a setting in which published salvage remission rates are approximately 13% and median survival approximately 2. 4 months - shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part A Preliminary blinded CR of 24% and CRc of 37% (n=62), with essentially identical rates among the 30 patients who had failed first-line venetoclax: CR of 23% and CRc of 37% (3X the published salvage remission rates following first-line venetoclax failure of approximately 13%) Enrollment reaches 74 of 90 patients, with final Part A treatment expected in September 2026 and comprehensive unblinded Part A results on track for the planned December 2026-February 2027 timeframe No evidence of cardiotoxicity continues to differentiate Annamycin from conventional anthracyclines HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.
